Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Cash from Financing Activities of -$112000.0 for Q1 2026, down 146.86% year-over-year from $239000.0 in Q1 2025, and up 7.44% quarter-over-quarter from -$121000.0 in Q4 2025.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Cash from Financing Activities for 4 consecutive years, with -$112000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 146.86% year-over-year to -$112000.0; the TTM figure through Mar 2026 stood at -$342000.0 (down 100.21% YoY), while the FY2025 annual figure was $9000.0, down 99.99% from the prior year.
- Cash from Financing Activities grew to -$112000.0 in Q1 2026 per ARTV's latest filing, from -$121000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $163.9 million in Q3 2024 and bottomed at -$121000.0 in Q4 2025.
- Historically, Cash from Financing Activities has averaged $20.9 million across 4 years, with a median of -$30000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 599.38% — and 2025, when it plunged 303.33%.
- Artiva Biotherapeutics' Cash from Financing Activities stood at $962000.0 in 2023, then sank by 103.12% to -$30000.0 in 2024, then slumped by 303.33% to -$121000.0 in 2025, then rose by 7.44% to -$112000.0 in 2026.
- Business Quant data shows ARTV's Cash from Financing Activities at -$112000.0 in Q1 2026, -$121000.0 in Q4 2025, and -$37000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - | 283.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 283.27 Mn |
| Mar 31, 2026 | -112,000.00 |
| Dec 31, 2025 | -121,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Jun 30, 2025 | -72,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | 163.87 Mn |
| Dec 31, 2023 | 962,000.00 |
| Sep 30, 2023 | 23.43 Mn |